NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, News, & Analysis

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its quarterly earnings data on Tuesday, August, 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.20. The firm had revenue of $117.75 million for the quarter, compared to the consensus estimate of $128.22 million. Ionis Pharmaceuticals had a negative net margin of 7.20% and a negative return on equity of 1.22%. View Ionis Pharmaceuticals' Earnings History.

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Ionis Pharmaceuticals.

8 brokers have issued 12 month price targets for Ionis Pharmaceuticals' stock. Their predictions range from $30.00 to $75.00. On average, they expect Ionis Pharmaceuticals' share price to reach $52.8750 in the next year. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.

Some companies that are related to Ionis Pharmaceuticals include Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE) and Sarepta Therapeutics (SRPT).

News articles about IONS stock have trended somewhat positive on Monday, according to Accern. Accern identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of 0.11 on Accern's scale. They also assigned headlines about the company an impact score of 45.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Ionis Pharmaceuticals.

Ionis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Baillie Gifford & Co. (7.39%), BB Biotech AG (6.90%), BlackRock Inc. (5.62%), OppenheimerFunds Inc. (2.14%) and Wells Fargo & Company MN (0.96%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Motley Fool Asset Management LLC, Pinnacle Associates Ltd., ARK Investment Management LLC, Renaissance Technologies LLC, Millennium Management LLC, California Public Employees Retirement System, GSA Capital Partners LLP and Tanaka Capital Management Inc.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., First Light Asset Management LLC, Peregrine Capital Management LLC, Motley Fool Wealth Management LLC, Los Angeles Capital Management & Equity Research Inc., Sicart Associates LLC, BB Biotech AG and BlackRock Inc.. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $51.67.

Ionis Pharmaceuticals has a market capitalization of $6.69 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.